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Edited by Robert BaroukiAbstract Cellular fatty acid uptake is facilitated by a number
of fatty acid transporters, FAT/CD36, FABPpm and FATP1.
It had been presumed that FABPpm, was conﬁned to the plasma
membrane and was not regulated. Here, we demonstrate for the
ﬁrst time that FABPpm and FATP1 are also present in intracel-
lular depots in cardiac myocytes. While we conﬁrmed previous
work that insulin and AICAR each induced the translocation
of FAT/CD36 from an intracellular depot to the PM, only AI-
CAR, but not insulin, induced the translocation of FABPpm.
Moreover, neither insulin nor AICAR induced the translocation
of FATP1. Importantly, the increased plasmalemmal content of
these LCFA transporters was associated with a concomitant in-
crease in the initial rate of palmitate uptake into cardiac myo-
cytes. Speciﬁcally, the insulin-stimulated increase in the rate of
palmitate uptake (+60%) paralleled the insulin-stimulated in-
crease in plasmalemmal FAT/CD36 (+34%). Similarly, the
greater AICAR-stimulated increase in the rate of palmitate up-
take (+90%) paralleled the AICAR-induced increase in both
plasmalemmal proteins (FAT/CD36 (+40%) + FABPpm
(+36%)). Inhibition of palmitate uptake with the speciﬁc FAT/
CD36 inhibitor SSO indicated that FABPpm interacts with
FAT/CD36 at the plasma membrane to facilitate the uptake of
palmitate. In conclusion, (1) there appears to be tissue-speciﬁc
sensitivity to insulin-induced FATP1 translocation, as it has been
shown elsewhere that insulin induces FATP1 translocation in
3T3-L1 adipocytes, and (2) clearly, the subcellular distribution
of FABPpm, as well as FAT/CD36, is acutely regulated in car-
diac myocytes, although FABPpm and FAT/CD36 do not neces-
sarily respond identically to the same stimuli.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Fatty acid transport; Translocation; FABPpm;
FATP1; FAT/CD361. Introduction
Long chain fatty acids (LCFAs) are a principal source of en-
ergy for many tissues including the heart, which receives
approximately 70% of its energy from LCFA oxidation [1].
While LCFAs are known to be taken up by cells through pas-
sive diﬀusion [2], other recent evidence has shown that LCFA*Corresponding author. Fax: +1 519 763 5902.
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mediated mechanism [3–5] involving at least one or more
LCFA binding proteins, including fatty acid translocase
(FAT/CD36) [6,7], fatty acid transport proteins FATP1–6
[8–10], and plasma membrane associated fatty acid binding
protein (FABPpm) [11–13].
Recently, it was shown that FAT/CD36 and FATP1 are in-
volved in the acute regulation of LCFA uptake. In heart and
skeletal muscle, contraction [14,15] and insulin [16,17] are able
to increase LCFA transport as a consequence of the transloca-
tion of FAT/CD36 from an intracellular pool(s) to the plasma
membrane. Similarly, insulin-induced translocation of FATP1
stimulates LCFA uptake into 3T3 L1 adipocytes [18]. These in-
creased rates of LCFA transport are associated with increased
rates of LCFA oxidation and esteriﬁcation during contractile
activity and insulin stimulation, respectively [15,17,19].
FABPpm is also a participant in trans-sarcolemmal LCFA
transport in skeletal muscles [11,13]. FABPpm is identical to
mitochondrial aspartate aminotransferase (mAspAT), which
binds to the inner mitochondrial membrane, and is associated
with the a-ketoglutarate dehydrogenase complex [20–22].
Transfecting 3T3 ﬁbroblasts with mAspAT-cDNA induced
the expression of plasmalemmal FABPpm, which resulted in
saturable rates of LCFA transport [12]. It has been assumed
that plasmalemmal FABPpm is not regulated acutely to pro-
mote the trans-membrane transport of LCFAs. However, this
assumption may not be valid. We [23] have shown that plasma-
lemmal FABPpm can be increased while the total cellular con-
tent of FABPpm was not altered, suggesting the presence of a
recruitable intracellular FABPpm pool. Recent studies, using
immunogold labelling of FABPpm, indicate that in some tis-
sues, but not all, FABPpm is also present in intra-cellular sites
other than mitochondria [24]. These observations begin to sug-
gest strongly that this LCFA transporter could be present in an
intracellular depot from which it could be induced to translo-
cate to the plasma membrane. But to date there is no evidence
that (a) FABPpm can be recruited to the plasma membrane
and whether (b) its translocation to the plasma membrane will
increase the rate of fatty acid acid uptake. Therefore, we exam-
ined in cardiac myocytes (i) whether there is an intracellular
depot of FABPpm, and (ii) whether FABPpm can be translo-
cated from this intracellular depots to the plasma membrane
(a) by insulin stimulation or (b) by AMP-kinase activation
(AICAR stimulation), since these stimuli induce the transloca-
tion of FAT/CD36 [15–17]. In addition, (iii) we also examinedblished by Elsevier B.V. All rights reserved.
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and AICAR on its subcellular redistribution. This was under-
taken since insulin induces the translocation of FATP1 in 3T3
L1 adipocytes, but there is no certainty that this protein is sim-
ilarly regulated in the heart. Importantly, we also determined
(iv) whether the insulin-induced or AICAR-induced transloca-
tion of one or more of these LCFA transporters stimulated the
rates of palmitate uptake.2. Materials and methods
2.1. Materials
FAT/CD36 and FABPpm were detected using the MO25 antibody
[25] and FABPpm antisera [26], respectively. The MCT-1 antibody
was a gift (Dr H. Hatta, University of Tokyo). Cox-4, FATP-1 and
secondary antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). [1-14C]Palmitate was purchased from Amersham
Life Science (Little Chalfont, UK). BSA (fraction V, essentially FA
free (conﬁrmed in separate analyses)) and phloretin were obtained
from Sigma–Aldrich (St. Louis, MO). Collagenase type II was pur-
chased from Worthington (Lakewood, NJ, USA). Insulin (Humulin-
R) was purchased from Eli-Lilly, Toronto, ON. The cell-permeant
adenosine analog 5-aminoimidazole-4-carboxamide-1-b-D-ribofurano-
side (AICAR) was obtained from Toronto Research Chemicals Inc.,
North York, ON, Canada. All other chemicals were obtained from
Sigma-Aldrich (St. Louis, MO). Sulfo-N-succinimidyl oleate (SSO) is
routinely synthesized in our laboratory [15]. Male Wistar rats (250–
300 g) were bred on site and maintained at 20 C on a reverse light–
dark cycle in approved animal holding facilities. They had unrestricted
access to food and water. This study was approved by the committee
on animal care at the University of Guelph.
2.2. Methods
Cardiac myocytes were isolated from adult rats as we have described
in detail elsewhere [15,16]. Subsequently, cardiac myocytes were incu-
bated (37 C) for 30 min with or without additions of AICAR (2 mM)
or insulin (10 nM). For all the experiments P 80% of the cardiac myo-
cytes were structurally intact. We examined the eﬀects of AICAR and
insulin on the total myocyte content of FAT/CD36, FABPpm, FATP-
1, and MCT1 in crude membranes, as well as on the subcellular
compartmentation of these proteins using Western blotting as we have
described elsewhere [15,16].
To detect the subcellular distribution of fatty acid transporters, plas-
ma membranes (PM) and low density microsomes (LDM) were iso-
lated from cardiac myocytes as we have previously described [15,16].
Signals obtained by Western blotting were quantiﬁed by densitometry
(SynGene, ChemiGenius2, Perkin Elmer, ON).
To examine the eﬀects of AICAR (2 mM), insulin (10 nM) and SSO
(0.4 mM) on the initial rates of palmitate uptake by cardiac myocytes
we used the procedures that we have previously described [15,16].
Brieﬂy, cardiac myocytes were incubated for 30 min with either insulin
or AICAR and during the last 3 min of the incubation a [1-14C]-palm-
itate-BSA complex was added (ﬁnal palmitate concentration 100 lM,
palmitate/BSA ratio of 0.3). In the studies in which SSO was used to
inhibit palmitate uptake, cardiac myocytes were pre-incubated with
this inhibitor for 15 min, after which the cells were washed twice. In
all treatments, palmitate uptake was stopped by adding an ice-cold
stop solution (KHB buﬀer supplemented with 0.1% BSA (w/v),
1 mM CaCl2 and 0.2 mM phloretin). Subsequently, cells were washed
twice with the stop solution at 60 · g for 2 min. The ﬁnal pellet was as-
sayed for radioactivity.
All data are expressed as means ± S.E.M. We used a t test to deter-
mine the statistical signiﬁcance, which was set at P 6 0.05.Fig. 1. Presence of FAT/CD36, FATP-1, FABPpm, Cox-4 and MCT1
in plasma membranes (PM) and low density membranes (LDM)
prepared from cardiac myocytes. MCT-1 and Cox-4 were not detected
in low density microsomes (LDM). In plasma membranes (PM) Cox-4
was not detected. Data are representative of ﬁve independent deter-
minations (means ± S.E.M.).3. Results
3.1. Identiﬁcation of intracellular FABPpm, FATP-1 and FAT/
CD36 depots in cardiac myocytes
Because we have recently shown that FAT/CD36 is present
in mitochondria [27,28], and it is well known that FABPpm(also known as aspartate aminotransferase) is present in
mitochondria [21,22], it was important to determine that
the LDM and PM fractions were not contaminated with
mitochondria. For these purposes we used MCT1 and Cox-
4. MCT1 is known to be conﬁned to the PM and mitochon-
dria, while it is not present in LDM [29–31]. In the present
study, we conﬁrmed that MCT1 was present only in the
PM fraction, not in the LDM fraction (Fig. 1). The absence
of COX-4 in the LDM and PM fractions (Fig. 1) conﬁrms
that the fractions were not contaminated with mitochondria.
Thus, our fractionation procedures successfully provided dis-
tinct PM and LDM fractions that were not contaminated
with each other, nor with mitochondria. We also conﬁrmed
our previous work [15,16] that FAT/CD36 is present in the
PM and LDM fractions. In addition, we show for the ﬁrst
time, that in cardiac myocytes FABPpm and FATP-1 are
present not only in the PM, but also in the LDM fractions
(Figs. 1 and 2C and G).
3.2. Eﬀects of insulin and AICAR on fatty acid transporters
(FAT/CD36, FABPpm, FATP-1)
The 30 min insulin and AICAR treatment did not alter the
protein expression of the LCFA transporters, FAT/CD36,
FABPpm, and FATP-1, nor the monocarboxylate transporter
MCT1 (Fig. 2A–H, P > 0.05).
3.2.1. Insulin. Insulin failed to induce the redistribution of
FABPpm as well as FATP-1 from the LDM to the PM (Fig.
2B and C, P > 0.05). As expected, insulin had no eﬀect on
MCT1, which is not present in the LDM (Fig. 2D). We con-
ﬁrmed our [16] previous observation that insulin induced the
translocation of FAT/CD36 from the LDM (32%,
P < 0.05) to the PM (+34%, P < 0.05) in cardiac myocytes
(Fig. 2A).
3.2.2. AICAR. In marked contrast to the failure of insu-
lin signaling to translocate FABPpm, AICAR induced the
translocation of FABPpm from the LDM (27%, P < 0.05)
Fig. 3. Eﬀects of insulin (10 nM, 30 min), AICAR (2 mM, 30 min) and
SSO (0.4 mM) on the initial rates of palmitate uptake by cardiac
myocytes. Data are based on ﬁve independent determinations for each
treatment (means ± S.E.M.). \P < 0.05, insulin vs control \\P < 0.05,
AICAR vs control and insulin \\\SSO vs control, insulin or AICAR.
Fig. 2. Eﬀects of insulin (10 nM, 30 min) and AICAR (2 mM, 30 min) on FAT/CD36, FABPpm, FATP-1 and MCT1 protein expression in cardiac
myocytes (Total) and plasma membranes (PM), and low density microsomes (LDM). Data are based on ﬁve independent determinations for each
treatment (means ± S.E.M.). ND: not detected. \P < 0.05, insulin or AICAR vs basal.
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eﬀect on FATP-1 redistribution (Fig. 2G), and as expected
did not aﬀect MCT1 at the PM (Fig. 2H). Previously, we
[15] had shown that oligomycin activated AMPK and in-
duced the translocation of FAT/CD36. In the present study,
AICAR, the well-known activator of AMPK, induced an in-
crease in FAT/CD36 at the PM (+40%, P < 0.05) and a con-
comitant FAT/CD36 reduction in the LDM (36%, P < 0.05)
(Fig. 2E).
3.2.3. Functional consequences of insulin- and AICAR-
induced translocation of LCFA transporters on the initial rates
of LCFA uptake. Incubations with insulin (10 nM), that in-
creased plasmalemmal FAT/CD36 (+34%) but not plasmalem-
mal FABPpm, stimulated the initial rates of palmitate uptake
(+60%, P < 0.05, Fig. 3). Incubation with AICAR (2 mM),
which increased the plasmalemmal content of both FAT/
CD36 (+40%) and FABPpm (+36%), also stimulated the initial
rates of palmitate uptake (+90%, P < 0.05, Fig. 3). Interest-
ingly, the increase in AICAR-stimulated rates of palmitate up-
take (+90%) was signiﬁcantly greater than the insulin-induced
increase in palmitate uptake (+60%, P < 0.05, Fig. 3). Blocking
of FAT/CD36 with the inhibitor SSO reduced the initial rates
of palmitate uptake to similar rates in all conditions examined
(Fig. 3), independent of the insulin- or AICAR-induced in-
crease in palmitate uptake.
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In the present study, we have a number of novel observa-
tions. We demonstrate for the ﬁrst time in cardiac myocytes
(a) that FABPpm and FATP-1 are present in LDM depots,
(b) that FABPpm can be translocated to the plasma membrane
when stimulated by AICAR, but not by insulin, and (c) that
FATP-1 redistribution is not altered either by insulin or by AI-
CAR. Importantly, (d) the increase in the initial rates of palm-
itate uptake induced by insulin (+60%) and by AICAR (+90%)
parallels the increase in the insulin-induced plasmalemmal
FAT/CD36 (+34%), and the sum of the AICAR-induced in-
crease in plasmalemmal FAT/CD36 (+40%) and plasmalem-
mal FABPpm (+36%). This study has now also conﬁrmed
our [15,16] previous observations that either AMPK activation
or insulin can induce the translocation of FAT/CD36 to the
plasma membrane in cardiac myocytes.
The increase in the plasmalemmal content of FABPpm, in-
duced by AICAR, was not attributable to the increased expres-
sion of this protein. We [16] have previously shown that our
fractionation procedures permit us to detect insulin-induced
GLUT4 translocation in cardiac myocytes. Moreover, the
PM and LDM fractions were free of mitochondrial contamina-
tion, and the LDM fraction was not contaminated with the
plasma membrane. Thus, we have carefully established that
FABPpm and FATP-1 are present in an intracellular depot,
as well as at the PM. We had previously established a similar
subcellular distribution for FAT/CD36 [15,16].4.1. FABPpm translocation from intracellular pool(s) to the
plasma membranes
As far as we are aware, there is no information in the liter-
ature, concerning the redistribution of FABPpm from an
endosomal pool to the plasma membrane. Interestingly, our
previous studies had suggested that this protein could be relo-
cated to the plasma membrane [23]. Speciﬁcally, in hearts of
obese Zucker rats there was an increase in LCFA transport,
which was associated with an increase in plasmalemmal FAB-
Ppm, as well as plasmalemal FAT/CD36, while the expression
of these proteins was not altered [23].
In the present study, only AICAR induced the translocation
of FABPpm from LDM to the PM. This responsiveness to AI-
CAR, but not to insulin, contrasts markedly with the insulin-
and AICAR-induced translocation of FAT/CD36 [15,16].
Since AICAR is well known to activate AMP-kinase [15], it
is tempting to speculate that FABPpm is recruited to the PM
at times when there is a requirement for an enhanced rate of
LCFA oxidation, which may assist, in an unknown manner,
with the targeting of LCFAs to the mitochondria. This is cur-
rently under investigation.
The LDM FABPpm depots are not only found in cardiac
myocytes. We have also determined that such a pool also exists
in skeletal muscle (Chabowski and Bonen, unpublished data).
Whether the intracellular depot of FABPpm in skeletal muscle
is also uniquely sensitive to AICAR but not to insulin remains
to be established.4.2. Insulin or AICAR fail to induce FATP1 translocation in
cardiac myocytes
Both insulin and AICAR failed to translocate FATP-1 from
intracellular depots to the plasma membranes. These resultsare in marked contrast with studies in which insulin-treated
3T3-L1 adipocytes showed rapid redistribution of FATP-1 to
the plasma membranes [18]. The non-recruitability of FATP1,
suggests that in cardiac myocytes this LCFA transporter is
stored in an intracellular membrane compartment that is dif-
ferent from recycling endosomes. It was also shown recently
that FATP1 concentrations in the heart are far less than
FATP6 concentrations [32], suggesting perhaps, that in the
heart FATP1 likely has a minor role in transporting LCFAs
[32]. This may be a reason why this protein is not induced to
translocate in the heart. Alternatively, other stimuli may in-
duce the translocation of this protein in the heart. Since the ef-
fects of insulin on FATP1 diﬀer in adipose tissue and the heart,
it will be important to ascertain whether FATP1 can be in-
duced to translocate in other tissues such as skeletal muscle,
where it is more predominatly expressed than other FATP iso-
forms [8–10].4.3. FAT/CD36 translocation from intracellular pool(s) to the
plasma membranes
Our present results are in agreement with our recent work
showing that insulin [16,17], and AICAR [15] or muscle con-
traction [14] induce the translocation of FAT/CD36 from
LDM to PM in skeletal muscles [14,17] and in the heart
[15,16]. The eﬀects of insulin and contraction on LCFA uptake
are additive in skeletal muscle [19] and in cardiac myocytes
[15]. This implies that there may be diﬀerent intracellular pools
of the FAT/CD36, which are sensitive to insulin- and contrac-
tion-mediated signals. Evidence for distinct insulin and con-
traction recruitable LDM depots has been shown for
GLUT4 [33].4.4. Eﬀects of insulin and AICAR on LCFA uptake by cardiac
myocytes
An important aspect of our study was to establish whether
the AICAR- and insulin-induced translocation of the LCFA
transporters resulted in changes in the initial rates of LCFA
uptake by cardiac myocytes. We observed that the changes
in the initial rates of LCFA uptake were closely correlated with
changes in plasmalemmal LCFA transporters. For example,
when insulin induced the translocation of only FAT/CD36 to
the PM (+34%), there was a concomitant increase in LCFA
uptake (+60%). However, this increase in the initial rate of
palmitate uptake was far greater (+90%), when AICAR in-
duced the translocation of both plasmalemmal FAT/CD36
(+40%) and FABPpm (+36%) to the PM, compared to when
only FAT/CD36 was induced to translocate. Thus, our study
indicates that altered rates of fatty acid uptake are strongly
associated with concomitant changes in the subcellular translo-
cation of LCFA transporters from the LDM to the PM.
It is not possible to ascertain conclusively from our study
whether the increased plasmalemmal FABPpm acts indepen-
dently, or acts in concert with FAT/CD36, to increase LCFA
uptake. However, the data strongly indicate that FABPpm
and FAT/CD36 interact with each other, as there appears to
be additional gain of function when both FAT/CD36 and
FABPpm are induced to translocate to the plasma membrane,
compared to when only FAT/CD36 is translocated to the plas-
ma membrane. These observations alone do not establish
whether these 2 proteins act independently to facilitate palmi-
tate uptake. However, FAT/CD36 inhibition with SSO
2432 A. Chabowski et al. / FEBS Letters 579 (2005) 2428–2432lowered the rates of palmitate uptake, either when FAT/CD36
alone was translocated to the plasma membrane, or when both
FAT/CD36 and FABPpm were translocated to the plasma
membrane. This is the strongest evidence to date that at the
functional level these two proteins interact at the plasma mem-
brane to facilitate the uptake of palmitate, and concurs with
previous speculations about their mode of action [34,35]. We
recognize that another fatty acid transporter, FATP-6, could
also be involved in promoting insulin and/or AICAR stimu-
lated uptake of palmitate in the heart since this protein has re-
cently been shown to be more abundant in heart than FATP1.
However, in the absence of any measurements of FATP6 we
cannot speculate about its role in palmitate uptake in cardiac
myocytes.5. Conclusions
We have provided several novel observations; (1) the discov-
ery of FABPpm and FATP-1 in cardiac myocytes LDM de-
pot(s), (2) the ability to induce the redistribution of
FABPpm from the LDM to the PM by AICAR, but not by
insulin, and (3) the translocation of the LCFA transporters
to the PM increases the initial rates of LCFA uptake into car-
diac myocytes in proportion to the two fatty acid transporters
(FAT/CD36 and FABPpm) at the plasma membrane.
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